文献速递胸部肿瘤放疗放疗物理与技术

局部晚期非小细胞肺癌:保留同侧正常肺的呼吁——DART-bid(剂量分化加速放疗,1.8 Gy 每日两次)联合 VMAT 的前瞻性临床试验

Locally advanced NSCLC: a plea for sparing the ipsilateral normal lung-prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) by VMAT.
PubMed 文献 · Radiat Oncol · 2022-07-07

这项前瞻性临床试验纳入100例连续未选择的II至IVA期局部晚期非小细胞肺癌患者,采用VMAT实施DART-bid方案(1.8 Gy每日两次,间隔8小时),原发肿瘤剂量73.8-90.0 Gy与肿瘤体积正相关,淋巴结61.2 Gy、选择性淋巴结45 Gy,放疗前给予两周期铂类化疗,12例完成度伐利尤单抗维持治疗。中位随访全组19.4个月、存活患者27.0个月(3.4-66.5个月)。2级和3级肺炎发生率分别为12%和2%,与文献中最大研究相比2级及以上肺炎风险降低有统计学意义(p<0.0006);未发生急性4/5级毒性,两例致死性肺出血不能排除与治疗相关。

要点

  • 100例连续未选择的II至IVA期LA-NSCLC患者接受VMAT-DART-bid治疗,未发生急性4/5级毒性。
  • 2级和3级肺炎发生率分别为12%和2%,与文献最大研究相比2级及以上肺炎风险降低有统计学意义(p<0.0006)。
  • 两例致死性肺出血不能排除与治疗相关。

核心结论

  • 总体毒性低;与文献结果相比,最大程度保留同侧正常肺显著降低肺炎风险。

研究设计与样本

  • 前瞻性临床试验,纳入100例连续未选择的II至IVA期局部晚期非小细胞肺癌患者(UICC/AJCC第8版)。
  • 原发肿瘤VMAT剂量73.8-90.0 Gy与肿瘤体积正相关,淋巴结61.2 Gy,受限体积淋巴结选择性45 Gy,分次剂量1.8 Gy每日两次、间隔8小时。
  • 放疗前给予两周期铂类化疗,12例完成度伐利尤单抗维持治疗;全组中位随访19.4个月,存活患者27.0个月(3.4-66.5个月)。
  • 试验在奥地利福拉尔贝格伦理委员会注册(EK-0.04-105),2017年4月9日注册,为回顾性注册。

主要发现

  • 未发生急性4/5级毒性;2级和3级肺炎分别见于12%和2%的患者。
  • 与文献中调查LA-NSCLC肺炎的最大研究相比,2级及以上肺炎风险降低有统计学意义(p<0.0006)。
  • 急性食管毒性1级、2级和3级分别见于12%、57%和3%的患者;两例出现2级晚期支气管狭窄/肺不张。
  • 两例致死性肺出血不能排除与治疗相关。
  • 全部III期患者及符合「RTOG 0617纳入标准」患者的中位总生存分别为46.6个月和50.0个月。

局限性

  • 试验为回顾性注册(2017年4月9日注册)。
  • 两例致死性肺出血不能排除与治疗相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In radiation treatment of locally advanced non-small cell lung cancer (LA-NSCLC), 'margins' from internal target volumes to planning target volumes in the range of 12 to 23 mm are reported, and avoiding exposure of the contralateral lung is common practice. We investigated prospectively an approach with tight margins (7 mm) and maximal sparing of the ipsilateral normal lung. Mature results for the first endpoint (pneumonitis) and further toxicities are reported. METHODS: Primary tumors were treated by VMAT with 73.8-90.0 Gy in positive correlation to tumor volumes, nodes with 61.2 Gy, a restricted volume of nodes electively with 45 Gy. Fractional doses of 1.8 Gy bid, interval 8 h. Before radiotherapy, two cycles platin-based chemotherapy were given. 12 patients finished maintenance therapy with Durvalumab. Median follow up time for all patients is 19.4 months, for patients alive 27.0 months (3.4-66.5 months). RESULTS: 100 consecutive, unselected patients with LA-NSCLC in stages II through IVA were enrolled (UICC/AJCC, 8th edition). No acute grade 4/5 toxicity occurred. Pneumonitis grade 2 and 3 was observed in 12% and 2% of patients, respectively; lowering the risk of pneumonitis grade ≥ 2 in comparison to the largest study in the literature investigating pneumonitis in LA-NSCLC, is significant (p < 0.0006). Acute esophageal toxicity grade 1, 2 and 3 occurred in 12%, 57% and 3% of patients, respectively. Two patients showed late bronchial stricture/atelectasis grade 2. In two patients with lethal pulmonary haemorrhages a treatment correlation cannot be excluded. Median overall survival for all stage III patients, and for those with 'RTOG 0617 inclusion criteria' is 46.6 and 50.0 months, respectively. CONCLUSIONS: Overall toxicity is low. In comparison to results in the literature, maximal sparing the ipsilateral normal lung lowers the risk for pneumonitis significantly. TRIAL REGISTRATION: Ethics committee of Vorarlberg, Austria; EK-0.04-105, Registered 04/09/2017-Retrospectively registered. http://www.ethikkommission-vorarlberg.at.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wurstbauer K, Kazil M, Meinschad M, et al. Locally advanced NSCLC: a plea for sparing the ipsilateral normal lung-prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) by VMAT. Radiat Oncol. 2022. PMID: 35799182. doi:10.1186/s13014-022-02083-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。